Anthera Pharma (ANTH) Tops Q4 EPS by 10c

Anthera Pharma (NASDAQ: ANTH) reported Q4 EPS of ($0.18), $0.10 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $1.92 million versus the consensus estimate of $150 thousand.

Cash and cash equivalents totaled $47 million as of December 31, 2015, compared to $2.6 million as of December 31, 2014. The increase in cash was mainly attributable to our March and July public offerings of common stock, sale of common stock through an at-the-market program, equity investment and cost reimbursement from Zenyaku, and a research grant from Cystic Fibrosis Foundation Therapeutics (“CFFT”), offset by cash used in operations.

For earnings history and earnings-related data on Anthera Pharma (ANTH) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
• Bristow Group to acquire Berry Aviation for $105 million